KANSAS CITY, Mo., March 1, 2025 /PRNewswire/ — Todd Hayes, COO of Adams Automotive and Auto Shop Answers, is set to take the stage Sunday morning 8:00 AM at VISION 2025 with a bold challenge to industry norms. His session, “How Can This Be Wrong?”, will introduce Auto Hospitality, a revolutionary approach to customer service… Continue reading Todd Hayes at VISION 2025: “How Can This Be Wrong?”
Tag: M and A
NMRA Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Neumora Therapeutics, Inc. (NMRA) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit
RADNOR, Pa., March 1, 2025 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement… Continue reading NMRA Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Neumora Therapeutics, Inc. (NMRA) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit
ALAR Investors Have Opportunity to Lead Alarum Technologies Ltd. Securities Fraud Lawsuit
NEW YORK, March 1, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alarum Technologies Ltd. (NASDAQ: ALAR) between March 14, 2024 and August 26, 2024, both dates inclusive (the “Class Period”), of the important April 15, 2025 lead plaintiff deadline. So what: If you purchased Alarum… Continue reading ALAR Investors Have Opportunity to Lead Alarum Technologies Ltd. Securities Fraud Lawsuit
Sucraid® (sacrosidase) Oral Solution. Free 4-Day Trial Now Available. The only FDA- approved therapy to treat CSID (Congenital Sucrase-Isomaltase Deficiency)
VERO BEACH, Fla., March 1, 2025 /PRNewswire/ — QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid® (sacrosidase) Oral Solution has been shown to be 81% effective in treating patients with Congenital Sucrase-Isomaltase Deficiency (CSID) when used appropriately.1 Eligible patients can now try Sucraid® for free with a 4-day trial offer through… Continue reading Sucraid® (sacrosidase) Oral Solution. Free 4-Day Trial Now Available. The only FDA- approved therapy to treat CSID (Congenital Sucrase-Isomaltase Deficiency)
CROCS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Crocs, Inc. – CROX
NEW ORLEANS, Feb. 28, 2025 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 24, 2025 to file lead plaintiff applications in a securities class action lawsuit against Crocs, Inc. (NasdaqGS: CROX), if they purchased the Company’s shares… Continue reading CROCS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Crocs, Inc. – CROX
ATI Reaches Tentative Agreement with United Steelworkers
DALLAS, Feb. 28, 2025 /PRNewswire/ — ATI Inc. (NYSE: ATI) announced that a tentative agreement has been reached with the leadership of the United Steelworkers (USW) on a new six-year Master Contract. This tentative agreement will be presented to the USW general membership for respective ratification votes. The previous contract was set to expire at 11:59… Continue reading ATI Reaches Tentative Agreement with United Steelworkers
EIX Investors Have Opportunity to Lead Edison International Securities Fraud Lawsuit Filed by the Rosen Law Firm
NEW YORK, March 1, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edison International (NYSE: EIX) between February 25, 2021 and February 6, 2025, both dates inclusive (the “Class Period”), of the important April 21, 2025 lead plaintiff deadline in the securities class action first filed by… Continue reading EIX Investors Have Opportunity to Lead Edison International Securities Fraud Lawsuit Filed by the Rosen Law Firm
TIXT Investors Have Opportunity to Lead TELUS International (Cda) Inc. Securities Fraud Lawsuit
NEW YORK, March 1, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TELUS International (Cda) Inc. (NYSE: TIXT) between February 16, 2023 and August 1, 2024, both dates inclusive (the “Class Period”), of the important March 31, 2025 lead plaintiff deadline. So what: If you purchased TELUS International… Continue reading TIXT Investors Have Opportunity to Lead TELUS International (Cda) Inc. Securities Fraud Lawsuit
EIX Investors Have Opportunity to Lead Edison International Securities Fraud Lawsuit Filed by the Rosen Law Firm
NEW YORK, March 1, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edison International (NYSE: EIX) between February 25, 2021 and February 6, 2025, both dates inclusive (the “Class Period”), of the important April 21, 2025 lead plaintiff deadline in the securities class action first filed by… Continue reading EIX Investors Have Opportunity to Lead Edison International Securities Fraud Lawsuit Filed by the Rosen Law Firm
Todd Hayes at VISION 2025: “How Can This Be Wrong?”
KANSAS CITY, Mo., March 1, 2025 /PRNewswire/ — Todd Hayes, COO of Adams Automotive and Auto Shop Answers, is set to take the stage Sunday morning 8:00 AM at VISION 2025 with a bold challenge to industry norms. His session, “How Can This Be Wrong?”, will introduce Auto Hospitality, a revolutionary approach to customer service… Continue reading Todd Hayes at VISION 2025: “How Can This Be Wrong?”